Last edition
News about Clinical Trials
MindRank Doses First Patient in Phase III Trial of AI-Designed Oral GLP-1RA MDR-001 in China
MindRank has initiated its Phase III MOBILE trial of MDR-001, an AI-designed oral GLP-1 receptor agonist, evaluating long-term efficacy and safety in 750 obesity and type 2 diabetes patients in China.
Clinical Trials | 02/03/2026 | By News Bureau | 151
Johnson & Johnson Submits sBLA to US FDA for IMAAVY in Warm Autoimmune Hemolytic Anemia
Johnson & Johnson has filed a supplemental biologics application seeking US approval of IMAAVY (nipocalimab) for warm autoimmune hemolytic anemia, a rare disorder with no currently approved treatments.
Clinical Trials | 26/02/2026 | By News Bureau | 138
Hansa Biopharma's Imlifidase BLA Accepted by US FDA for Priority Review
FDA accepts Hansa Biopharma’s BLA for imlifidase, supported by strong Phase III ConfIdeS data demonstrating significant kidney function improvement in highly sensitized transplant patients.
Clinical Trials | 20/02/2026 | By News Bureau | 256
Novartis' Remibrutinib Shows Positive Phase III Results in Chronic Inducible Urticaria
Pivotal RemIND trial meets primary endpoint across three major CIndU subtypes, positioning oral remibrutinib as a potential first targeted therapy for inducible chronic hives.
Clinical Trials | 19/02/2026 | By News Bureau | 124
Iberdomide, an investigational oral CELMoD therapy, is under FDA review in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma.
Clinical Trials | 19/02/2026 | By News Bureau | 109
Duvakitug Shows Durable Efficacy in Ulcerative Colitis and Crohn's Disease in Long-Term Study
Long-term extension data show sustained remission and endoscopic response with duvakitug in ulcerative colitis and Crohn’s disease, strengthening its position as a potential next-generation TL1A therapy.
Clinical Trials | 18/02/2026 | By News Bureau | 148
Genentech's Gazyva Shows Strong Phase III Results in Primary Membranous Nephropathy
Phase III MAJESTY trial shows Gazyva significantly improves complete remission rates in primary membranous nephropathy, potentially paving the way for the first targeted therapy for the condition.
Clinical Trials | 17/02/2026 | By News Bureau | 112
Lilly's Retevmo Shows Significant Benefit in Early-Stage RET+ Lung Cancer in Phase III Trial
LIBRETTO-432 study demonstrates statistically significant improvement in event-free survival as adjuvant therapy for stage II–IIIA RET fusion-positive NSCLC.
Clinical Trials | 17/02/2026 | By News Bureau | 135
CStone's CS2009 Secures U.S. FDA IND Clearance for Phase II Trial in Advanced Solid Tumours
CStone Pharmaceuticals has received U.S. FDA IND clearance to begin a Phase II trial of its trispecific antibody CS2009 for advanced solid tumours, advancing its global immunotherapy development programme.
Clinical Trials | 16/02/2026 | By News Bureau | 115
HeriCare-Breast01 study evaluates next-generation HER2 ADC against standard THInnovent BiologicsP regimen, following promising phase I/II efficacy and safety data presented at ASCO 2025.
Clinical Trials | 16/02/2026 | By News Bureau | 122
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy